Results 1 to 10 of about 21,302 (228)

Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples

Research and Practice in Thrombosis and Haemostasis, 2022
Background DOAC Filter (DF) is a new device to overcome interference in lupus anticoagulant (LAC) testing by direct oral anticoagulants (DOACs). Objectives We evaluated DOAC removal from plasma and elimination of DOAC interference in LAC testing by DF ...
Eleni A. Linskens, Pieter De Kesel, Katrien M. J. Devreese   +2 more
doaj   +2 more sources

Evaluation of DOAC Dipstick Test for Detecting Direct Oral Anticoagulants in Urine Compared with a Clinically Relevant Plasma Threshold Concentration

Clinical and Applied Thrombosis/Hemostasis, 2022
Measuring direct oral anticoagulant (DOAC) concentrations might be necessary in certain clinical situations but is not routinely performed. The DOAC Dipstick is a new rapid test for detecting DOACs in urine.
Lenna Örd MD, Toomas Marandi MD, PhD, Marit Märk MD, Leonid Raidjuk MD, Jelena Kostjuk MD, Valdas Banys MD, PhD, Karit Krause, Marika Pikta MD   +7 more
doaj   +2 more sources

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

Research and Practice in Thrombosis and Haemostasis, 2021
Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with ...
Steven Andrew Baker, Jing Jin, Christopher Pfaffroth, Trang Vu, James L. Zehnder   +4 more
doaj   +2 more sources

Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients [PDF]

Vojnosanitetski Pregled, 2022
Background/Aim. Direct oral anticoagulants (DOACs) administration significantly interferes with coagulation as-says. The aim of the study was to evaluate the effect of DOACs and DOAC-Remove® on coagulation assays during thrombophilia testing.
Kovač Mirjana, Basarić Dušica, Tomić Branko, Gvozdenov Maja, Backović Dragana, Lalić-Ćosić Sanja   +5 more
doaj   +5 more sources

DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation

Thrombosis and Haemostasis, 2022
AbstractIn certain clinical situations, it is necessary to determine whether clinically relevant plasma levels of direct oral anticoagulants (DOACs) are present. We examined whether qualitative testing of DOACs in urine samples can exclude DOAC plasma concentrations of ≥30 ng/mL. This prospective single-center cohort study included consecutive patients
Margetić, Sandra, Ćelap, Ivana, Lovrenčić Huzjan, Arijana, Bosnar Puretić, Marijana, Šupraha Goreta, Sandra, Glojnarić, Anesa Čajević, Delić Brkljačić, Diana, Mioč, Pavao, Harenberg, Job, Hetjens, Svetlana, Weiss, Christel   +10 more
openaire   +3 more sources

DOAC drug interactions management resource

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2022
Background Over the past decade, direct oral anticoagulants (DOACs; apixaban, dabigatran, edoxaban and rivaroxaban) have offered many advantages over traditional therapy with warfarin ± low-molecular-weight heparins (LMWHs).
Ayush Chadha, Micheal Guirguis, Tammy J. Bungard   +2 more
openaire   +3 more sources

Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests [PDF]

TH Open, 2018
AbstractThe impact of direct oral anticoagulants (DOACs) on laboratory assays used for thrombophilia testing (e.g., antithrombin, protein S, protein C, lupus anticoagulant and activated protein-C resistance) is a well-known issue and may cause false-positive and -negative results.
Favresse, Julien, Lardinois, Benjamin, Sabor, Lina, Devalet, Bérangère, Vandepapeliere, Julie, Braibant, Maximilien, Lessire, Sarah, Chatelain, Bernard, Jacqmin, Hugues, Douxfils, Jonathan; id_orcid 0000-0002-7644-5298, Mullier, François   +10 more
openaire   +5 more sources

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients [PDF]

Journal of Stroke, 2023
Background and Purpose In patients with acute ischemic stroke (AIS) using a direct oral factor-Xa anticoagulant (DOAC) during the last 48 hours, a fixed plasma heparin-calibrated anti-Xa activity (0.5 IU/mL) was proposed as a threshold below which ...
Charlyne Brakta, Alain Stépanian, Peggy Reiner, Maxime Delrue, Mikaël Mazighi, Emmanuel Curis, Virginie Siguret   +6 more
doaj   +1 more source

Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity [PDF]

Journal of Stroke, 2022
Background and purpose In acute stroke patients, plasma concentrations of direct oral anticoagulants (DOAC) at hospital admission only poorly mirror DOAC exposure or the coagulation status at the time of the event.
Timolaos Rizos, Andreas D. Meid, Andrea Huppertz, Chris Dumschat, Jan Purrucker, Kathrin I. Foerster, Jürgen Burhenne, David Czock, Ekkehart Jenetzky, Peter A. Ringleb, Walter E. Haefeli   +10 more
doaj   +1 more source

Prevention of thrombotic complications in patients in the postoperative period of total hip and knee arthroplasty: efficacy and safety

Евразийский Кардиологический Журнал, 2023
Thromboembolic complications (TEC) remain a significant problem in modern surgery, worsening the prognosis and reducing the effectiveness of the operation performed.
A. M. Ushanova, E. A. Okisheva, O. Iu. Mironova   +2 more
doaj   +1 more source